Analyst Reco. ADC Therapeutics SA

Equities

ADCT

CH0499880968

Market Closed - Nyse Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
3.43 ^USD	-0.29%		-6.79%	+106.63%

May. 30	Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating	MT
May. 07	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating	May. 30	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	May. 07	MT
Guggenheim Initiates ADC Therapeutics With Buy Rating, $11 Price Target	Mar. 28	MT
RBC Lifts Price Target on ADC Therapeutics to $8 From $6, 'Encouraged' by Competitive Positioning; Outperform, Speculative Risk Kept	Feb. 26	MT
HC Wainwright Raises Price Target on ADC Therapeutics to $9 From $3, Maintains Buy Rating	Feb. 20	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics to $3 From $12, Keeps Buy Rating	Nov. 20	MT
TD Cowen Downgrades ADC Therapeutics to Market Perform From Outperform	Nov. 09	MT
RBC Cuts Price Target on ADC Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	Nov. 08	MT
RBC Trims Price Target on ADC Therapeutics to $8 From $9 Amid Guidance Withdrawal, Keeps Outperform, Speculative Risk	23-09-12	MT
JPMorgan Upgrades ADC Therapeutics to Neutral From Underweight	23-08-10	MT
RBC Trims Price Target on ADC Therapeutics to $9 From $10, Maintains Outperform Rating, Speculative Risk Qualifier	23-08-09	MT
HC Wainwright Lowers Price Target on ADC Therapeutics to $12 From $20, Maintains Buy Rating	23-06-20	MT
RBC Cuts Price Target on ADC Therapeutics to $10 From $12, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-10	MT
BofA Securities Downgrades ADC Therapeutics to Underperform From Neutral, Adjusts Price Target to $2 From $7	23-04-24	MT
RBC Cuts Price Target on ADC Therapeutics to $12 From $18, Maintains Outperform, Speculative Risk	23-02-13	MT
Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalweight Rating	23-01-24	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $21, Maintains Buy Rating	23-01-04	MT
Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Equal-Weight Rating	22-11-14	MT
BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $14	22-11-09	MT
RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cami Launch; Maintains Outperform, Speculative Risk Rating	22-11-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ADC Therapeutics SA

Equities

ADCT

CH0499880968

Analyst Reco.

Filters